Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

NCT07811297 is registered in ClinicalTrials.gov with Advenchen Pharmaceuticals, LLC. as lead sponsor.

NCT NCT07811297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2031
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial neoplasms, glioblastoma, ovarian neoplasms, soft tissue sarcoma (sts)